Zynerba Pharmaceuticals, Inc.

DB:6ZY Stock Report

Market Cap: €61.8m

Zynerba Pharmaceuticals Valuation

Is 6ZY undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 6ZY when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 6ZY (€1.23) is trading below our estimate of fair value (€56.18)

Significantly Below Fair Value: 6ZY is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 6ZY?

Key metric: As 6ZY is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for 6ZY. This is calculated by dividing 6ZY's market cap by their current book value.
What is 6ZY's PB Ratio?
PB Ratio2.3x
BookUS$29.02m
Market CapUS$65.60m

Price to Book Ratio vs Peers

How does 6ZY's PB Ratio compare to its peers?

The above table shows the PB ratio for 6ZY vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average6x
0RX Redx Pharma
16.6x-22.3%€65.0m
HIGH Cantourage Group
1.3x112.7%€57.6m
APPH Apontis Pharma
2.6x78.1%€80.3m
2FJ0 Pierrel
3.6xn/a€92.8m
6ZY Zynerba Pharmaceuticals
2.3x67.2%€65.6m

Price-To-Book vs Peers: 6ZY is expensive based on its Price-To-Book Ratio (2.3x) compared to the peer average (1x).

Price to Book Ratio vs Industry

How does 6ZY's PB Ratio compare vs other companies in the European Pharmaceuticals Industry?

11 CompaniesPrice / BookEstimated GrowthMarket Cap
6ZY 2.3xIndustry Avg. 2.3xNo. of Companies17PB0246810+
11 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: 6ZY is expensive based on its Price-To-Book Ratio (2.3x) compared to the European Pharmaceuticals industry average (2x).

Price to Book Ratio vs Fair Ratio

What is 6ZY's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

6ZY PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio2.3x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate 6ZY's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 6ZY forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentn/a
€1.15
0%
11.6%€1.29€1.02n/a2
Nov ’25n/a
€1.15
0%
11.6%€1.29€1.02n/a2
Oct ’25n/a
€1.15
0%
11.6%€1.29€1.02n/a2
Sep ’25n/a
€1.15
0%
11.6%€1.29€1.02n/a2
Aug ’25n/a
€1.15
0%
11.6%€1.29€1.02n/a2
Jul ’25n/a
€1.15
0%
11.6%€1.29€1.02n/a2
Jun ’25n/a
€1.15
0%
11.6%€1.29€1.02n/a2
May ’25n/a
€1.15
0%
11.6%€1.29€1.02n/a2
Apr ’25n/a
€1.15
0%
11.6%€1.29€1.02n/a2
Mar ’25n/a
€1.15
0%
11.6%€1.29€1.02n/a2
Feb ’25n/a
€1.15
0%
11.6%€1.29€1.02n/a2
Jan ’25n/a
€1.15
0%
11.6%€1.29€1.02n/a2
Dec ’24n/a
€1.15
0%
11.6%€1.29€1.02n/a2
Nov ’24n/a
€1.15
0%
11.6%€1.29€1.02n/a2
Oct ’24€1.23
€1.15
-6.2%
11.6%€1.29€1.02n/a2
Sep ’24€1.16
€1.15
-0.5%
11.6%€1.29€1.02n/a2
Aug ’24€0.32
€5.32
+1,574.5%
69.1%€9.18€0.37n/a3
Jul ’24€0.27
€5.32
+1,901.9%
69.1%€9.18€0.37n/a3
Jun ’24€0.33
€4.70
+1,332.0%
72.1%€9.21€0.37n/a4
May ’24€0.35
€4.93
+1,324.4%
74.2%€10.09€0.46n/a4
Apr ’24€0.38
€4.93
+1,199.3%
74.2%€10.09€0.46n/a4
Mar ’24€0.45
€5.13
+1,046.3%
71.9%€10.38€0.72n/a4
Feb ’24€0.60
€5.13
+752.0%
71.9%€10.38€0.72n/a4
Jan ’24€0.52
€5.13
+885.8%
71.9%€10.38€0.72n/a4
Dec ’23€0.52
€6.22
+1,104.7%
57.9%€10.62€0.73n/a4
Nov ’23€0.72
€6.39
+788.0%
56.0%€10.82€0.98n/a4

Analyst Forecast: Target price is lower than the current share price.

Discover undervalued companies

Teva Pharmaceutical Industries

US$18.9b

Develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.

TEV

US$16.05

7D

4.9%

1Y

79.5%

Pharming Group

€492.8m

A biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally.

PHGN

€0.71

7D

0.4%

1Y

-33.2%

Collegium Pharmaceutical

US$966.2m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

354

US$28.60

7D

2.1%

1Y

21.2%